产品说明书

Tariquidar

Print
Chemical Structure| 206873-63-4 同义名 : XR9576
CAS号 : 206873-63-4
货号 : A251517
分子式 : C38H38N4O6
纯度 : 98%
分子量 : 646.731
MDL号 : MFCD09837824
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 15 mg/mL(23.19 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：

IP 3% DMSO+3% Tween80+40% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 60 mg/mL suspension

生物活性
靶点

  • P-gp

    P-gp, Kd:5.1 nM
描述 The multidrug resistance is an obstacle in the chemotherapy treatment (such as doxorubicin, vincristine, paclitaxel, TKIs) for many solid and haematological tumours. Many factors can cause the multidrug resistance. Among them, the overexpression of P-gp (ABCB1), of which vinblastine and paclitaxel is the substrate, on the surface of resistant cells is considered as a key factor mediating multidrug resistance. Thus, the increased bioavailable and brain accumulation of anticancer drugs can be achieved partially through inhibition of P-gp. Tariquidar is a potent P-gp transport modulator with IC50 value of 0.4μM, displaying specific high-affinity binding to P-gp with Kd of 5.1nM. The cellular study showed that the accumulation of vinblastine and paclitaxel can be increased in a dose-dependent manner by tariquidar with EC50 value of 487nM and 25.4nM, respectively, in CHrB30 cells, not mediated through competition for transport[1]. Co-administration of paclitaxel with tariquidar (p.o., 50mg/kg) led to a comparable increase and a long lasting 5-fold increase in the concentration of paclitaxel accumulation in the cytostatic in the brain of nude mice[2].
作用机制 Tariquidar can bind at a site which is distinct from the site of interaction of transport substrates and alter P-gp-mediated transport by affecting its rate of ATP hydrolysis.[1]
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
A2780 cells Function assay 30 mins Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay, IC50=0.12589 μM 18083034
EMT6/AR1.0 cells Function assay 1 h Inhibition of mouse Pgp in EMT6/AR1.0 cells after 1 hr by daunorubicin accumulation assay, IC50=0.064 μM 18083034
human CCD-18Co cells Cytotoxic assay 48 h Cytotoxicity against human CCD-18Co cells assessed as cell viability after 48 hrs by MTT assay, IC50=25 μM 26197160
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01663545 - Completed - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01547754 - Terminated - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01386476 - Completed - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.55mL

0.31mL

0.15mL

7.73mL

1.55mL

0.77mL

15.46mL

3.09mL

1.55mL
参考文献

[1]Hubensack M, M¨¹ller C, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol. 2008 May;134(5):597-607. Epub 2007 Oct 12.

[2]Martin C, Berridge G, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999 Sep;128(2):403-11

[3]Bankstahl JP, Kuntner C, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med. 2008 Aug;49(8):1328-35.

[4]Foran E, Kwon DY, et al. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.

[5]Mistry P, Stewart AJ, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001 Jan 15;61(2):749-58.

[6]Matzneller P, Kussmann M, et al. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):599-606.